Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a ...